NCT04003623View on ClinicalTrials.gov

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 31, 2019

Primary Completion Date

June 12, 2020

Study Completion Date

June 12, 2020

Conditions
Advanced or Metastatic Solid TumorsFGFR MutationsFGFR Translocations
Interventions
DRUG

Pemigatinib

Pemigatinib administered orally once daily.

Trial Locations (11)

21702

FMH James M Stockman Cancer Institute, Frederick

34474

Ocala Oncology Center, Ocala

45220

TriHealth, Cincinnati

51704

Sanford Cancer Center, Sioux Falls

61615

Illinois Cancer Care, Peoria

75230

Mary Crowley Cancer Center, Dallas

77030

Oncology Consultants, Houston

84106

Utah Cancer Specialists, Salt Lake City

92708

Compassionate Cancer Care Medical Group, Fountain Valley

96813

Hawaii Cancer Care, Honolulu

07109

New Jersey Cancer Care and Blood Disorders, Belleville

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT04003623 - Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) | Biotech Hunter | Biotech Hunter